Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Chi Kin Wong(Lunenfeld-Tanenbaum Research Institute), Daniel J. Drucker(University of Toronto)
Cited by 38
Related Papers
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
|Endocrine Reviews|2020|268
Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation
|Cell Metabolism|2023|251
Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans
|Gastroenterology|1999|208
Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation
|Cell Metabolism|2022|121
Molecular Characterization of the 2011 Hong Kong Scarlet Fever Outbreak
|The Journal of Infectious Diseases|2012|112